Sponsored By

Bioventus Needs to Find Another Way to Pay for CartiHeal

The company has nixed a $415 sale of senior notes that was meant to fund its acquisition of CartiHeal.

Amanda Pedersen

May 12, 2022

2 Min Read
Bioventus CEO headshot and quote about the business.png

Bioventus still wants to buy CartiHeal, but now the company will have to find a different way to finance the deal, which was announced just a month ago.

The Durham, NC-based company said it has withdrawn its offering of senior notes citing current market conditions and is exploring alternative financing options for the $315 million upfront payment to acquire CartiHeal. The deal also calls for an additional payment of about $135 million due upon the achievement of $100 million in trailing 12-month sales.

“We are encouraged by the momentum we’re seeing across our key short- and mid-term growth drivers, which position us for sustained double-digit growth,” said Bioventus CEO Ken Reali. “While we are no longer exploring a senior notes offering to finance an acquisition of CartiHeal, we are looking into alternative financing options.”

The company reaffirmed its full-year 2022 net sales guidance of $545 million to $565 million, based on current trends in its business.

"It's a difficult financing environment, and our goal is to try and find a possible alternative that will maximize stakeholder value in the near and long term," Reali said Tuesday during the company's first-quarter earnings call.

In addition to pursuing alternative financing options, Reali said Bioventus is "evaluating the rational feasibility of the acquisition, considering these financing alternatives."

Bioventus invested about $2.5 million in CartiHeal back in 2018 to support an ongoing clinical study of the Agili-C implant. The implant, which is designed to treat osteoarthritis, received a breakthrough device designation from FDA in 2020. Bioventus exercised its option to acquire Israel-based CartiHeal in April after FDA approved the Agili-C implant in late March.

"I want to enforce one thing," Reali said during the earnings call. "We believe in the Bioventus business and our ability to drive double-digit growth with or without CartiHeal."

He also called CartiHeal's technology a game changer, but said it is not a "finance-at-all-cost situation."

Bioventus is in discussions with its banks as well as with CartiHeal.

"Any financing consideration cannot and will not impair our ability to drive the significant potential we have with the Bioventus business today," Reali said. "So any options that we look at, that is the lens ... We're not going to get into specifics today on what we're looking at."

About the Author(s)

Amanda Pedersen

Amanda Pedersen is a veteran journalist and award-winning columnist with a passion for helping medical device professionals connect the dots between the medtech news of the day and the bigger picture. She has been covering the medtech industry since 2006.

Sign up for the QMED & MD+DI Daily newsletter.

You May Also Like